NEXT GENERATION CONDOM CONTRACEPTION TO TACKLE SEXUALLY TRANSMITTED DISEASES & UNINTENDED PREGNANCIES
CASE STUDY (Filmed October 2023, June 2024)
Eudaemon Technologies
Australia
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
In 2022 Eudaemon Technologies was awarded AUD$1.5m in funding to advance the clinical trial of their next generation condom project, awarded by the Medical Research Future Fund (MRFF) funding from the Australian Government’s Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect, and supported by MTAA.
Also, funding has come from NSW Health and The Office for Health and Medical Research.
According to Executive Chairman and Co-Founder Nick Northcott, the company has made significant progress in the past six months, including completing a pilot clinical trial involving 35 couples and achieving a major milestone.
“The completion of this Pilot Clinical Trial is a major milestone and value inflection point for the company. The Pilot Clinical data provides strong signal for safety, efficacy and consumer preference for Eudaemon’s Hydrogel Condom platform. We are now poised to move through scaling up our manufacturing, completing a Pivotal Clinical Trial prior to regulatory submission and then entering the market and commercialisation. A very exciting time for Eudaemon Tech as an Australian MedTech manufacturer.”, says Northcott.
Eudaemon Technologies is now focused on scaling up production and obtaining regulatory approval for commercialisation of their high-quality condoms. Once granted approval, the company is working towards scaling their manufacturing to produce the millions of units, with the ultimate aim to manufacture into the billions of high-quality condoms.
Eudaemon Technologies’ vision goes beyond the creation of a superior condom, as the company is ultimately contributing to an important global health cause. By assisting individuals in overcoming barriers to the consistent use of condoms through material innovation, the company endeavours to positively impact public health by mitigating the spread of STIs and reducing unplanned pregnancies on a global scale
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
Prescribing exercise to regional population with cardiovascular disease & diabetes
Associate Professor Gordon’s research is aimed at determining the optimal methods of prescribing and implementing exercise as part of the health care plan for people with cardiovascular disease and diabetes. Specifically, he is leading work to determine if and how the components of exercise can be considered as a whole for prescribing exercise to generate health benefits. This is important to overcome the series of barriers that people living in rural and regional areas experience when trying to become active.
-
Relationship between language-literacy skills and mental health
In an innovative move towards enhancing mental health services, Associate Professor Amanda Neil and team, supported by the RHH Research Foundation, are undertaking a crucial study on language-literacy skills of patients within mental health care settings. This year-long project, which commenced in April 2024, seeks to unravel to what extent, where and for whom language-literacy skills are being considered in Tasmanian mental health service provision.
